ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSKBAHRIS..MTNORSMESMMAKHTNMD..........*JBDM Ver 2.1.1 - 2999001/03638696CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120240626W154deBibliographieenBibliographyfrBibliographieEP18732064.3201806182020011620220830enenen20170967720170616GB2024062620242620200422202017202403062024102023100620240626202426C07K 16/28 20060101AFI20181221BHEP A61K 39/00 20060101ALI20181221BHEP A61K 39/39558 20130101 LI20190411BHEP A61K2300/00 20130101 LI20190411BHEP A61K 31/706 20130101 LI20190605BHEP A61K2300/00 20130101 LI20190605BHEP A61K2039/505 20130101 LA20180723BHEP C07K2317/22 20130101 LA20180723BHEP C07K2317/24 20130101 LA20180723BHEP C07K2317/41 20130101 LA20180723BHEP C07K2317/732 20130101 LA20180723BHEP C07K2317/734 20130101 LA20180723BHEP C07K2317/76 20130101 LA20180723BHEP C07K2317/94 20130101 LA20180723BHEP A61K 45/06 20130101 LI20190605BHEP C07K 16/2875 20130101 FI20180723BHEP A61P 35/02 20180101 LI20190411BHEP A61K 31/706 20130101 LI20190411BHEP A61K 39/39558 20130101 LI20190411BHEP deANWENDUNG VON ANTI CD70 ANTIKÖRPER ARGX-110, UM AKUTE MYELOID LEUKEMIE ZU BEHANDELNenUSE OF ANTI CD70 ANTIBODY ARGX-110 TO TREAT ACUTE MYELOID LEUKAEMIAfrUTILISATION DE L'ANTICORPS ANTI-CD70 ARGX-110 POUR TRAITER LA LEUCÉMIE MYÉLOÏDE AIGUËWO-A1-2012/123586DEMPKE WOLFRAM C M ET AL: "Second- and third-generation drugs for immuno-oncology treatment-The more the better?", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM, NL, vol. 74, 10 February 2017 (2017-02-10), pages 55-72, XP029933747, ISSN: 0959-8049, DOI: 10.1016/J.EJCA.2017.01.001J. JACOBS ET AL: "CD70: An emerging target in cancer immunotherapy", PHARMACOLOGY AND THERAPEUTICS., vol. 155, November 2015 (2015-11), pages 1-10, XP055289894, GB ISSN: 0163-7258, DOI: 10.1016/j.pharmthera.2015.07.007CARSTEN RIETHER ET AL: "CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 214, no. 2, 28 December 2016 (2016-12-28), pages 359-380, XP055735891, US ISSN: 0022-1007, DOI: 10.1084/jem.20152008MAY KUNG SUTHERLAND ET AL: "5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia", MABS LANDES BIOSCIENCE, vol. 24, 1 July 2010 (2010-07-01), pages 440-448, XP055096014, DOI: 10.4161/mabs.1220324160069.1438914220240227LEUPIN, Nicolasc/o argenx BVBA Industriepark Zwijnaarde 7 Building CB-9052 GentBEVAN ROMPAEY, Lucc/o argenx BVBA Industriepark Zwijnaarde 7 Building CB-9052 GentBEDE HAARD, Hansc/o argenx BVBA Industriepark Zwijnaarde 7 Building CB-9052 GentBEOCHSENBEIN, AdrianBreitenrain 283032 HinterkappelenCHRIETHER, CarstenGesellschaftsstrasse 443012 BernCHargenx BV101992423EOR/P153963EP00Industriepark-Zwijnaarde 79052 Zwijnaarde (Ghent)BEUniversity of Bern101906737EOR/P153963EP00Verwaltungsdirektion Hochschulstrasse 63012 BernCHBoult Wade Tennant LLP101370347Salisbury Square House 8 Salisbury SquareLondon EC4Y 8APGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTRBA20200116ME20200116KH20200116MA20200116MD20200116TN20200116EP201806614420180618enWO201822930320181220201851